Novo's New US Chief on Lilly's Rival Weight-Loss Pill
Novo Nordisk Executive Vice President for US Operations Jamey Millar discusses the US approval of competitor Eli Lilly's obesity pill, the expansion of the GLP-1 category, and the rollout of a new subscription model. He talks with Katie Greifeld for "The Close."


_1373454_640x360_2494733379941-640x360.webp&w=3840&q=75)
_1373452_640x360_2494728259926-640x360.webp&w=3840&q=75)



_1373421_640x360_2494726723793-640x360.webp&w=3840&q=75)

_1373410_640x360_2494720579886-640x360.webp&w=3840&q=75)